CUDC 305

Drug Profile

CUDC 305

Alternative Names: CU-0305; CUDC-305; DEBIO 0932; Debio-0932

Latest Information Update: 28 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Curis
  • Developer Curis; Debiopharm
  • Class 2 ring heterocyclic compounds; Antineoplastics; Benzodioxoles; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • No development reported Cancer
  • Discontinued Lymphoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 20 Sep 2018 Aarhus University Hospital plans a proof of-concept phase Ib trial for Plaque psoriasis in Denmark (NCT03675542)
  • 28 Jun 2018 No recent reports of development identified for phase-I development in Cancer in USA (PO)
  • 19 Jun 2015 CUDC 305 is available for licensing as of 19 Jun 2015. http://www.curis.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top